Rigel Pharmaceuticals Future Growth
Future criteria checks 2/6
Rigel Pharmaceuticals is forecast to grow earnings and revenue by 6.5% and 7.4% per annum respectively. EPS is expected to decline by 3.7% per annum. Return on equity is forecast to be 42.5% in 3 years.
Key information
6.5%
Earnings growth rate
-3.73%
EPS growth rate
| Biotechs earnings growth | 23.9% |
| Revenue growth rate | 7.4% |
| Future return on equity | 42.46% |
| Analyst coverage | Low |
| Last updated | 22 Dec 2025 |
Recent future growth updates
Recent updates
If EPS Growth Is Important To You, Rigel Pharmaceuticals (NASDAQ:RIGL) Presents An Opportunity
Nov 27
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Price Is Right But Growth Is Lacking After Shares Rocket 35%
Nov 12Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion
Sep 26Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 23% Discount?
Sep 25Benign Growth For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Underpins Stock's 26% Plummet
Sep 25Does Rigel Pharmaceuticals (NASDAQ:RIGL) Have A Healthy Balance Sheet?
Sep 03Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Held Back By Insufficient Growth Even After Shares Climb 28%
Aug 06Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) CEO Compensation Looks Acceptable To Us And Here's Why
May 15Rigel Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 09Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Not Doing Enough For Some Investors As Its Shares Slump 26%
Apr 02Rigel Looks Interesting, But Let's Wait For A Lower Price
Mar 11
Advancing Pipeline And Partnerships Will Drive Future Success
Strong growth in the commercial portfolio is driven by increased demand and strategic expansions, especially with products like GAVRETO and TAVALISSE.Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Held Back By Insufficient Growth Even After Shares Climb 38%
Feb 06Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 28% Price Drop
Dec 20Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate
Nov 08Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships
Oct 10Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth
Sep 25There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise
Jul 30Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential
Jul 24Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding
May 01Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 08Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 336 | 124 | 67 | N/A | 5 |
| 12/31/2026 | 292 | 99 | 26 | N/A | 5 |
| 12/31/2025 | 291 | 120 | N/A | N/A | 5 |
| 9/30/2025 | 282 | 113 | 68 | 68 | N/A |
| 6/30/2025 | 268 | 98 | 66 | 66 | N/A |
| 3/31/2025 | 203 | 37 | 35 | 36 | N/A |
| 12/31/2024 | 179 | 17 | 31 | 31 | N/A |
| 9/30/2024 | 157 | 4 | 10 | 11 | N/A |
| 6/30/2024 | 130 | -14 | -13 | -12 | N/A |
| 3/31/2024 | 119 | -20 | -7 | -7 | N/A |
| 12/31/2023 | 116 | -25 | -21 | -6 | N/A |
| 9/30/2023 | 129 | -24 | -36 | -21 | N/A |
| 6/30/2023 | 121 | -38 | -49 | -33 | N/A |
| 3/31/2023 | 125 | -45 | -67 | -52 | N/A |
| 12/31/2022 | 116 | -59 | -74 | -74 | N/A |
| 9/30/2022 | 86 | -83 | -71 | -71 | N/A |
| 6/30/2022 | 87 | -85 | -68 | -68 | N/A |
| 3/31/2022 | 77 | -85 | -1 | 0 | N/A |
| 12/31/2021 | 139 | -18 | 5 | 6 | N/A |
| 9/30/2021 | 138 | -15 | 8 | 9 | N/A |
| 6/30/2021 | 136 | -8 | -1 | 0 | N/A |
| 3/31/2021 | 131 | -11 | -70 | -69 | N/A |
| 12/31/2020 | 109 | -30 | -53 | -52 | N/A |
| 9/30/2020 | 106 | -28 | -48 | -46 | N/A |
| 6/30/2020 | 108 | -25 | -43 | -41 | N/A |
| 3/31/2020 | 102 | -28 | -46 | -44 | N/A |
| 12/31/2019 | 59 | -67 | -43 | -42 | N/A |
| 9/30/2019 | 82 | -46 | -21 | -20 | N/A |
| 6/30/2019 | 66 | -59 | N/A | -26 | N/A |
| 3/31/2019 | 57 | -64 | N/A | -36 | N/A |
| 12/31/2018 | 45 | -70 | N/A | -59 | N/A |
| 9/30/2018 | 7 | -100 | N/A | -90 | N/A |
| 6/30/2018 | 3 | -93 | N/A | -88 | N/A |
| 3/31/2018 | 1 | -87 | N/A | -80 | N/A |
| 12/31/2017 | 4 | -78 | N/A | -78 | N/A |
| 9/30/2017 | 7 | -68 | N/A | -70 | N/A |
| 6/30/2017 | 10 | -73 | N/A | -75 | N/A |
| 3/31/2017 | 19 | -67 | N/A | -74 | N/A |
| 12/31/2016 | 20 | -69 | N/A | -76 | N/A |
| 9/30/2016 | 26 | -66 | N/A | -77 | N/A |
| 6/30/2016 | 35 | -50 | N/A | -64 | N/A |
| 3/31/2016 | 32 | -51 | N/A | -64 | N/A |
| 12/31/2015 | 29 | -51 | N/A | -23 | N/A |
| 9/30/2015 | 29 | -61 | N/A | -25 | N/A |
| 6/30/2015 | 16 | -75 | N/A | -34 | N/A |
| 3/31/2015 | 10 | -87 | N/A | -35 | N/A |
| 12/31/2014 | 8 | -91 | N/A | -70 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RIGL's forecast earnings growth (6.5% per year) is above the savings rate (3.3%).
Earnings vs Market: RIGL's earnings (6.5% per year) are forecast to grow slower than the US market (16.2% per year).
High Growth Earnings: RIGL's earnings are forecast to grow, but not significantly.
Revenue vs Market: RIGL's revenue (7.4% per year) is forecast to grow slower than the US market (10.7% per year).
High Growth Revenue: RIGL's revenue (7.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RIGL's Return on Equity is forecast to be very high in 3 years time (42.5%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/26 01:25 |
| End of Day Share Price | 2025/12/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rigel Pharmaceuticals, Inc. is covered by 21 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Birchenough | Barclays |
| James Birchenough | BMO Capital Markets Equity Research |
| Clarence Powell | BMO Capital Markets Equity Research |